Healthcare Stock Insights: Vivus Wins FDA Diet Drug THUMBS UP, StemCells Give BACK

Vivus Inc. (NASDAQ:VVUS) shares predictably jump, on word that the FDA okayed its weight-loss drug Qnexa/Qsymia on Wednesday, even though they has plummeted just before the announcement. At the same time, shares of Vivus’ competitors Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc. (NASDAQ:OREX) reacted oppositely to the news.

Don’t Miss: Vivus VIVACIOUS! Second U.S. Diet Drug Approved in 13 Years.

Galena Biopharma, Inc. (GALE) shares pop on the news of a key patent that covers the use of its NeuVax product candidate for breast cancer patients having low-to-intermediate IHC levels, and which represents an important unmet medical need with as much as 80 percent of patients who can not qualify for Herceptin therapy.

Shares of StemCells, Inc. (NASDAQ:STEM) return a portion of Tuesday’s more than a 100 percent rise, on a spate of profit-taking Wednesday morning. On Tuesday, shares went through the roof subsequent to the firm’s announcement of positive results from its Alzheimer’s preclinical trials, which indicated memory restoration and enhanced synaptic function after transplanting human neural stem cells into animal models.

Don’t Miss: InterMune Second Quarter Earnings Sneak Peek.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.